Manganese Inhibits Viability of Prostate Cancer Cells

Anticancer Res. 2018 Jan;38(1):137-145. doi: 10.21873/anticanres.12201.


Background/aim: Androgen deprivation therapy is usually in the initial phase a successful treatment for prostate cancer but eventually most patients develop androgen-independent metastatic disease. This study investigated if manganese (Mn) reduces viability of prostate cancer via induction of apoptosis.

Materials and methods: The prostate cancer cell lines PC3, DU145 and LNCaP underwent dose- and time-dependent screening of viability, analyzed by the 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay. Flow cytometry was used for the cell-cycle and apoptosis analyses. Intracellular Mn concentration was measured using inductively coupled plasma-mass spectrometry.

Results: At Mn concentrations of 200-1000 μM, the effect on viability was most pronounced in PC3 followed by LNCaP cells. These cell lines also showed higher intracellular concentration of Mn compared to DU145. In all cell lines, Mn increased the proportion of cells arrested in the G0/G1 phase and induced apoptosis.

Conclusion: To our knowledge, this is the first report demonstrating Mn as a potential agent in prostate cancer therapy.

Keywords: DU145; LNCaP; Manganese; PC3; apoptosis; cell viability; prostate cancer.

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Cell Cycle / drug effects
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Humans
  • Male
  • Manganese / pharmacology*
  • Prostatic Neoplasms / drug therapy*


  • Antineoplastic Agents
  • Manganese